Westbrook, Maine-based IDEXX Laboratories, Inc. (IDXX) is a world chief in veterinary diagnostics, software program, and water testing options. Valued at a market cap of $52.5 billion, it develops, manufactures, and distributes merchandise for the companion animal veterinary, livestock and poultry, dairy, and water testing industries.
Firms value $10 billion or extra are sometimes categorized as “large-cap shares,” and IDXX matches the label completely. With its deal with innovation, digital options, and recurring diagnostic revenues, the corporate performs a key function in advancing animal well being, meals security, and water high quality worldwide.
Shares of the veterinary big have decreased 4.7% from its 52-week excessive of $688.12, reached on Aug. 4. Shares of IDXX have soared 26.4% over the previous three months, significantly outperforming the Well being Care Choose Sector SPDR Fund’s (XLV) 3.3% return throughout the identical time-frame.
In the long term, IDXX inventory has rallied 36.5% over the previous 52 weeks, outpacing XLV’s 10.6% downtick over the identical time interval. Furthermore, on a YTD foundation, shares of IDXX are up 58.6%, in comparison with XLV’s marginal return.
To substantiate its bullish pattern, IDXX has been buying and selling above its 200-day and 50-day shifting averages since late April, with slight fluctuations.
On Aug. 4, shares of IDXX skyrocketed 27.5% after its sturdy Q2 2025 earnings launch. The corporate reported income of $1.1 billion, up 10.6% year-over-year and three.7% above the consensus estimates. Furthermore, its EPS improved by a formidable 48.8% from the year-ago quarter to $3.63, topping analyst expectations by a notable margin of 9.7%. Noting its strong bottom-line efficiency, IDXX additionally raised its fiscal 2025 EPS outlook, additional bolstering investor confidence. It now expects it to be between $12.40 and $12.76.
IDXX’s outperformance seems much more pronounced when in comparison with its rival, Zoetis Inc. (ZTS), which declined 21.9% over the previous 52 weeks and eight.1% on a YTD foundation.
Regardless of IDXX’s outperformance, analysts stay cautiously optimistic about its prospects. The inventory has a consensus ranking of “Average Purchase” from the 12 analysts protecting it, and the imply worth goal of $722.60 is a premium of 10.2% to present ranges.
On the date of publication, Neharika Jain didn’t have (both straight or not directly) positions in any of the securities talked about on this article. All data and information on this article is solely for informational functions. This text was initially printed on Barchart.com
